论文部分内容阅读
目的:观察胸腺肽联合保肝类药物对原发性肝癌的治疗效果。方法:设立治疗组和对照组,对治疗组患者使用胸腺肽联合保肝类药物,并将其治疗效果与对照组的保肝支持治疗效果加以比较。结果:治疗组症状体征、AFP及瘤体均有改善,在P<0.01的水平具备统计学显著差异。结论:使用胸腺肽联合保肝类药物有助于提高患者的生活质量并且实施起来简单有效。
Objective: To observe the therapeutic effect of thymosin combined with hepatoprotective drugs on primary liver cancer. Methods: The treatment group and the control group were set up. The patients in the treatment group were treated with thymopeptide combined with hepatoprotective drugs, and the therapeutic effect was compared with that of the control group. Results: The symptoms and signs, AFP and tumor in the treatment group were improved, with statistically significant differences at the P <0.01 level. Conclusion: The use of thymosin in combination with hepatoprotective drugs helps to improve the patient’s quality of life and is simple and effective to administer.